SR ONE CAPITAL MANAGEMENT, LP Q4 2024 Filing
Filed February 13, 2025
Portfolio Value
$410.1B
Holdings
11
Report Date
Q4 2024
Filing Type
13F-HR
All Holdings (11 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ACLXArcellx, Inc. | 2,346,630 | $180.0B | 43.88% | |
| 2 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $42.3B | 10.32% | |
| 3 | CRSPCRISPR Therapeutics AG | 1,048,951 | $41.3B | 10.07% | |
| 4 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $40.3B | 9.82% | |
| 5 | ZBIOZenas BioPharma, Inc | 4,911,539 | $40.2B | 9.81% | |
| 6 | MLYSMineralys Therapeutics Inc. | 2,016,822 | $24.8B | 6.05% | |
| 7 | ALMSAlumis Inc. | 1,959,896 | $15.4B | 3.76% | |
| 8 | ORKAOruka Therapeutics, Inc | 430,330 | $8.3B | 2.03% | |
| 9 | NKTXNkarta, Inc. | 3,333,333 | $8.3B | 2.02% | |
| 10 | ENGNenGene Holdings Inc. | 747,750 | $5.0B | 1.21% | |
| 11 | KALAKALA Bio, Inc. | 598,940 | $4.2B | 1.01% |